Strategic platform Position Kiromic as a clinical-stage, allogeneic Gamma Delta T-cell therapy developer leveraging DIAMOND AI 2.0 target discovery to shorten development timelines, highlighting opportunities to partner on off-the-shelf cell therapies for solid tumors.

Collaborations & partnerships Target potential alliances with biopharma and CROs seeking advanced immuno-oncology platforms, emphasizing the company’s end-to-end bioinformatic, AI-driven target discovery and manufacturing capabilities for joint IND programs and multi-indication trials.

Off-the-shelf focus Leverage the growing interest in off-the-shelf gamma delta T-cell therapies to offer licensing, co-development, or ASC/CMO engagement for scalable, ready-to-administer cancer therapies.

Funding & visibility Capitalize on fundraising activity and public coverage to approach Kiromic for strategic equity investments, milestone-driven collaborations, or value-adding partnerships that align with their revenue range and ongoing IND filings.

Clinical and regulatory momentum Monitor and engage around their INDs for Alexis-Pro-1 and Alexis-ISO-1, offering regulatory strategy support, clinical trial services, or companion diagnostics collaborations to accelerate regulatory submissions and market readiness.